Welgene Biotech Co.,Ltd. (TPEX:6661)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
18.15
-0.15 (-0.82%)
Apr 29, 2026, 1:30 PM CST
-10.15%
Market Cap 422.97M
Revenue (ttm) 375.94M
Net Income (ttm) 1.33M
Shares Out 23.30M
EPS (ttm) 0.06
PE Ratio 318.02
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 14,000
Average Volume 8,323
Open 18.35
Previous Close 18.30
Day's Range 17.80 - 18.35
52-Week Range 17.60 - 24.05
Beta 0.29
RSI 40.48
Earnings Date May 8, 2026

About Welgene Biotech

Welgene Biotech Co.,Ltd. engages in the trade of biotechnology-related instruments, reagents, and biotechnology testing services. The company offers research services, including generation, PacBio third generation sequencing; microarray, protein body analysis; nucleic acid extraction/QC, single cell experimental, and bioinformatics analysis services. It also provides reagents, medical consumables, and instruments, as well as software services. Welgene Biotech Co.,Ltd. was founded in 2003 and is based in Taipei City, Taiwan. [Read more]

Sector Healthcare
Founded 2003
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6661
Full Company Profile

Financial Performance

In 2025, Welgene Biotech's revenue was 375.94 million, an increase of 16.55% compared to the previous year's 322.55 million. Earnings were 1.33 million, an increase of 20.14%.

Financial Statements

News

There is no news available yet.